Insurer Can't Blame Drug Cos. For Its Inaction, 7th Circ. Told
Law360, Chicago (November 6, 2019, 2:28 PM EST) -- A Seventh Circuit judge on Wednesday pushed Medical Mutual of Ohio to address why it waited until July 2016 to take steps to limit which testosterone replacement drugs the insurer would cover, two years after the U.S. Food and Drug Administration flagged potential cardiovascular risks associated with the drugs.
During oral arguments, Medical Mutual urged the Seventh Circuit to revive its Racketeer Influenced and Corrupt Organizations Act suit against AbbVie and other makers of testosterone replacement drugs, or TRTs, saying they misrepresented those drugs as being safe and effective for a host of symptoms related to normal male aging.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!